Ongoing, recruitingHuman Pharmacology (Phase I)- OtherInterventional

A clinical study of MK-4646 in healthy people (MK-4646-002)

This is a very early stage study, called a Phase 1 trial, for a new medicine named MK-4646. It aims to understand how this new drug behaves in the human body. Researchers will give MK-4646 to healthy volunteers, not people with HIV, to see how it's absorbed, how long it stays in the body, and how it's processed. This helps them find a safe dose and look for any immediate side effects. The information gathered from healthy people is crucial before testing the medicine in those living with HIV. The study is open to adults aged 18 and over, irrespective of gender.

At a glance

Status

Ongoing, recruiting

Phase

Human Pharmacology (Phase I)- Other

Sponsor

Merck Sharp & Dohme LLC

Enrolment target

Start

18 Nov 2024

HIV infection

What is this study about?

Imagine scientists are developing a brand new car, but they haven't driven it outside a test track yet. This study is a bit like that initial test drive. It's a very early step in checking a new medicine called MK-4646. This medicine is eventually hoped to help people with HIV infection. However, before it can be given to people living with HIV, doctors need to understand how it works in generally healthy adults.

So, in this study, healthy volunteers will receive MK-4646. The main goals are to see how the medicine moves through the body, how quickly it's used up, and if there are any immediate side effects. This helps researchers figure out if the medicine is safe enough to proceed to larger studies and what dose might be appropriate. It’s about gathering basic, but very important, information about the drug's properties.

This type of research, known as a Phase 1 study, is essential for every new medicine. It helps ensure that when the medicine is eventually tested in people who could benefit from it, the researchers have already learned a lot about how it behaves and any potential challenges. Think of it as laying the groundwork for future, more advanced studies that could ultimately lead to new treatments for HIV.

Key takeaways

This is a very early stage study (Phase 1) for a new medicine called MK-4646.
It aims to understand how the medicine works and if it's safe in healthy people.
The findings will help decide if the medicine can be tested in people living with HIV in the future.
You must be 18 years or older and in generally good health to be considered.
Both men and women can take part.
Participation will involve taking a study medicine and regular health check-ups.

Who may be eligible?

This study is looking for healthy adults to take part. To be considered, you must be 18 years old or older. There is no upper age limit mentioned.

Both men and women are welcome to participate in this research. The study needs a variety of people to get a good understanding of how the medicine works in different individuals.

As this is a study for *healthy* people, you would generally need to be in good overall health. The study team will check your medical history to make sure that taking part would be safe for you.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you 18 years old or older?
Are you generally in good health?
Do you understand this study is for healthy people, not those with HIV?
Are you able to attend appointments at a study clinic?
Are you prepared to follow study instructions carefully?

Answer every question to see your result.

What does participation involve?

If you decide to take part, you would receive the study medicine, MK-4646. The study team would closely monitor your health. This usually involves several visits to the study clinic, where you might have blood tests, urine tests, and other health checks. You would be expected to follow specific instructions about taking the medicine and any food or drink restrictions. The total length of your participation would be explained to you in detail, but these early studies can involve a period of receiving medication followed by several follow-up visits to ensure your well-being and track the drug's effects.

Potential risks and benefits

Taking part in any study has potential benefits and risks. A potential benefit of this study is contributing to medical science and the development of new treatments for HIV. However, as this is a new medicine, there's a risk of unknown side effects, though the study team will monitor you very closely for any issues. You have the right to withdraw from the study at any time, for any reason, without it affecting your medical care.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

—
Unverified
Belgium

Common questions

What is HIV infection?

HIV (Human Immunodeficiency Virus) is a virus that attacks the body's immune system, which is our defence against infections and diseases. Without treatment, HIV can weaken the immune system, making it harder to fight off illnesses.

What does 'Phase 1' mean for a study?

Phase 1 is the very first stage of testing a new medicine in humans. It focuses on safety and how the drug works in the body, primarily using a small group of healthy volunteers.

Will I get paid for taking part?

Payment for participation in research studies varies. This would be something you should discuss directly with the study team.

Do I have to stop my current medicines to join?

The study team will review all your current medicines during the screening process to see if they might interfere with the study drug or your safety. They will advise you on whether you need to stop any medications.

What happens after this study?

If MK-4646 is found to be safe and behaves as expected in this study, it may then move on to later phases of research, which would involve testing it in people living with HIV.